Liquid Biopsy Market Size, Share, Trends, Growth 2032

Liquid Biopsy Industry Prospective:

The global liquid biopsy market size was worth around USD 5.71 billion in 2023 and is predicted to grow to around USD 16.22 billion by 2032 with a compound annual growth rate (CAGR) of roughly 12.3% between 2024 and 2032.

Request Free Sample

In order to give the users of this report a comprehensive view of the liquid biopsy market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

Liquid Biopsy Market: Growth Drivers

A biopsy is a tissue or cell sample taken from any part of the human body, which is sent to the lab for examining various disease types. A liquid biopsy is an advanced form of treatment procedure for cancer, wherein bodily fluids like blood or urine are collected for disease detection. National Cancer Institute (NCI) defines liquid biopsy as a test performed on a blood sample to identify cancer cells from a tumor circulating in blood or DNA via tumor cells in the blood. A liquid biopsy helps in planning treatment regime along with finding out effective treatment options for the patients. Through liquid biopsy, specialist physicians are able to track different molecular changes occurring within tumor cells and put forth appropriate treatment procedures.

The global liquid biopsy market growth can be attributed to the increasing incidences of cancer, growing demand for minimally invasive surgeries and personalized medicine, and rising healthcare expenditure. Stringent regulatory policies, lack of clarity in medical pricing, unclear reimbursement policies, and the presence of alternatives to liquid biopsies may restraint the liquid biopsy market growth over the forecast time period.

Request Free Sample

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, product, and regional expansion of major participants involved in the market.

Liquid Biopsy Market: Segmentation

The study provides a decisive view of the liquid biopsy market based on target analyte, analytical, sample, cancer type, end-user, and region.

The target analyte segment includes circulating tumor cells, circulating tumor DNA, exosomes, nucleosomes, and other biomarkers.

The analytical segment includes molecular, proteomic, and histology/imaging.

By cancer type, the market includes breast cancer, lung cancer, prostate cancer, colorectal cancer, brain cancer, and others.

The sample segment includes urine, blood, and others.

The end-user segment includes hospital, research laboratories, academia, and research centers.

Liquid Biopsy Market: Report Scope

Liquid Biopsy Market: Regional Analysis

The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The liquid biopsy market in the Asia Pacific region is estimated to show the highest CAGR over the forecast time period, owing to the rising cancer incidences, growing aging population, increasing privatization and deregulation within the healthcare sector, and provisional financing of health services across the region. Japan, Singapore, Australia, and the Republic of Korea remain key regional investors for liquid biopsy. Additionally, the global market will witness significant demand from developing economies like India and China.

North America and Europe are considered to be the foremost regions for liquid biopsy market in terms of revenue, due to the increasing R&D expenditure, clarity in the regulatory process, growing demand for minimally invasive surgeries, and high expenditure related to healthcare.

Liquid Biopsy Market: Competitive Analysis

The global liquid biopsy market is led by players like:

• Biocept
• Cynvenio
• NeoGenomics Laboratories
• Qiagen
• Trovagene
• RainDance Technologies
• Guardant Health
• Exosome Diagnostics
• SAGA Diagnostics AB
• Circulogene Theranostics
• Inivata
• Agena Bioscience
• Admeria Health Personal Genome Diagnostics
• Adaptive Biotechnologies

This report segments the global liquid biopsy market into:

Global Liquid Biopsy Market: Target Analyte Analysis

• Circulating Tumor Cells
• Circulating Tumor DNA
• Exosomes
• Nucleosomes
• Other Biomarkers

Global Liquid Biopsy Market: Analytical Analysis

• Molecular
• Proteomic
• Histology/Imaging

Global Liquid Biopsy Market: Application Analysis

• Routine Screening
• Patient Work Up
• Early-Stage Disease
• Late Stage/Metastatic Disease

Global Liquid Biopsy Market: Sample Analysis

• Blood
• Urine
• Others

Global Liquid Biopsy Market: Cancer Type Analysis

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Brain Cancer
• Prostate Cancer
• Others

Global Liquid Biopsy Market: End-User Analysis

• Hospitals
• Research Laboratories
• Academia
• Research Centers

Global Liquid Biopsy Market: Regional Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa